Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1120320180040020047
Osteoporosis and Sarcopenia
2018 Volume.4 No. 2 p.47 ~ p.52
The development of Taiwan Fracture Liaison Service network
Chang Lo-Yu

Tsai Keh-Sung
Peng Jen-Kuei
Chen Chung-Hwan
Lin Gau-Tyan
Lin Chin-Hsueh
Tu Shih-Te
Mao I-Chieh
Gau Yih-Lan
Liu Hsusan-Chih
Niu Chi-Chien
Hsieh Min-Hong
Chien Jui-Teng
Hung Wei-Chieh
Yang Rong-Sen
Wu Chih-Hsing
Chan Ding-Cheng
Abstract
Osteoporosis and its associated fragility fractures are becoming a severe burden in the healthcare system globally. In the Asian-Pacific (AP) region, the rapidly increasing in aging population is the main reason accounting for the burden. Moreover, the paucity of quality care for osteoporosis continues to be an ongoing challenge. The Fracture Liaison Service (FLS) is a program promoted by International Osteoporosis Foundation (IOF) with a goal to improve quality of postfracture care and prevention of secondary fractures. In this review article, we would like to introduce the Taiwan FLS network. The first 2 programs were initiated in 2014?at the National Taiwan University Hospital and its affiliated Bei-Hu branch. Since then, the Taiwan FLS program has continued to grow exponentially. Through FLS workshops promoted by the Taiwanese Osteoporosis Association (TOA), program mentors have been able to share their valuable knowledge and clinical experience in order to promote establishments of additional programs. With 22 FLS sites including 11 successfully accredited on the best practice map, Taiwan remains as one of the highest FLS coverage countries in the AP region, and was also granted the IOF Best Secondary Fracture Prevention Promotion award in 2017. Despite challenges faced by the TOA, we strive to promote more FLS sites in Taiwan with a main goal of ameliorating further health burden in managing osteoporotic patients.
KEYWORD
Asia-Pacific region, Taiwan, Fracture Liaison Service, Best Practice Framework, Osteoporosis
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed